The development of molecularly targeted cancer drugs is one of the most exciting advancements in oncology. The potential benefits from the identification of drug targets and the associated drugs and tests are illustrated by several novel examples, such as HER2/neu & Herceptin and Gleevec.
The rising incidence of cancer, particularly in the over 50 population, is likely have a significant impact on all areas of cancer treatment; however, for many cancer types, there remains a significant unmet need in effective treatment. Lung cancer is one example, as patient survival is less than five years after diagnosis.

Traditional therapies have failed to provide adequate redress for these patients, signifying a need for an alternative treatment plan. Programs, such as those that grant compassionate use, are becoming more common as provider and patients continue to demand better therapies with the potential for increasing life.

The targeted cancer therapeutics market specifically focuses on five leading segments of targeted therapies: monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, CDK inhibitors, proteasome inhibitors.

Additionally, smaller areas of targeted therapies are covered including mTOR inhibitors, PI3K inhibitors, PARP inhibitors, apoptosis inhibitors, histone deacetylase inhibitors, hedgehog signaling pathway inhibitors and several others.

The use of monoclonal antibodies in cancer therapy is currently the subject of intense investigation. Monoclonal antibodies specifically bind with target antigens and could, therefore, be used in several ways to treat cancer. Antibodies can be used to deliver a cytotoxic drug preferentially to the cancer cell and thus minimize drug interactions with normal cells. Similarly, antibodies can be used to direct other cytotoxic cells, such as macrophages and T cells, to tumor cells lurking in the body. Antibodies can be attached to a radioactive label and injected into a patient to screen for recurrence of tumor growth. Antibodies can also be directed against cells that support tumor growth.

The Advantage of Targeting

Targeted therapy is defined as the use of specific treatments and drugs tailored to each patient and to various types of cancer, in order to stop the spread of cancerous cells in the body with as few side effects or damage to healthy cells as possible. Advances in this field are coming fast and furious, according to specialists, and many new therapies work on a molecular level, using biological agents to stop cancerous and abnormal cells in their tracks.

According to the National Cancer Institute (NIH), targeted cancer therapies are different from standard therapies in the following ways:
• Targeted therapies act on specific molecular targets that are associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells.
• Targeted therapies are deliberately chosen or designed to interact with their target, whereas many standard chemotherapies were identified because they kill cells.
• Targeted therapies are often cytostatic (that is, they block tumor cell proliferation), whereas standard chemotherapy agents are cytotoxic (that is, they kill tumor cells).
The problem with many of the “broad” or traditional therapies is that they damage healthy cells while trying to eliminate cancerous cells.

Rising Incidence

As noted, the incidence of cancer is on the rise. In 2018, the International Agency for Research on Cancer reported that more than 18 million people were diagnosed with cancer. Of these, lung, breast, colorectal, prostate, stomach, liver and esophagus were the most commonly reported. Together, these account for nearly 10 million cases.

Worldwide between 40 and 45 million people are living with cancer and nearly 9.6 million people have died. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries. The risk of developing cancer before the age of 75 years is about 20.2%.

These data highlight the importance of effective cancer therapies in the current market; however, as we move toward 2040, the World Health Organization anticipates an increase to about 28 million new cases annually by 2040, a 62% increase over 2018.
Cancer is a disease characterized by uncontrolled cell proliferation. Despite more than 100 different types of cancer, those of the lung, breast, prostate, and colon-rectum account for nearly half of all new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers. Major advances in molecular medicine have shed light on the pathogenesis of cancer at the biochemical level.

Top Competitors

The top 15 market participants in targeted therapies, responsible for roughly 97% of targeted cancer therapy revenue, include:
• Johnson & Johnson (J&J)/Janssen
• AbbVie
• Amgen
• AstraZeneca
• Takeda Oncology – Millennium Pharms
• Eli Lilly
• Bayer
• Merck EMD Serono
• Exelixis
• Roche/Genentech
• Celgene
• Bristol-Myers Squibb (BMS)
• Novartis
• Merck
• Pfizer

Results below expectations, perhaps explained by one-time events, were coupled with new product launches and some silver lining in niche markets, as the top two IVD companies announced first-quarter results.  Roche’s Diagnostics division reported sales of $2.9 BN CHF (approx. $2.86 BN USD) and 1% growth, with Molecular Diagnostics as main contributor.  That was flat growth since last year the division grew 5% in the first quarter.

Roche is the world’s largest diagnostic company and its results can speak to the broader market.

The company claimed temporary events and one-time offsets dampened growth, and there were some unusual events in the quarter.  Distributor inventory reduction on point-of-care products in China and one time offsets in tissue diagnostics, also free-of-charge deliveries following the recall of CoaguChek test strips in the fourth quarter.

Within these results, a few events are notable for watchers of diagnostic markets:

  • Roche reported that its molecular Point of Care Sales Up 18%, as cobas Liat finds markets in physician offices and decentralized hospital testing locations.
  • Sales in cervical cancer diagnosis grew 52 percent and sales in blood screening grew 14 percent.
  • While Diabetes care grew 1%, growth was 18% in North America due to recent management care contract wins.
  • While sales in Japan and China were disappointing, EMEA sales were up 3% and Latin America was up 8%.

The company noted several product launches.   The Cobas VivoDx system for antibiotic resistance testing provides results in under 6 hours and can perform 96 tests per 8-hour shift.  NAVIFY mutation profiler combined with NAVIFY therapy matcher both [ph] as a curated knowledge base of genetic fragments to help interpret the clinical significance of the patients and identify suitable therapies. and the VENTANA PD-L1, SP142 Assay, the first FDA companion diagnostic approval for use in first line triple negative breast cancer or TNBC.

Kalorama Information’s Worldwide Market for In Vitro Diagnostic Tests provides market sizing and forecasting for all categories of the IVD market
Now in 11 Editions. 

Abbot Diagnostics grew .2% on a reported basis to $1.8 BN dollars, though currency effects clouded otherwise 4.4% organic growth.    Growth was driven by long-term double-digit growth in its Alinity molecular diagnostic platform and other products.  But due to lower flu test revenues , rapid diagnostic revenues, comprising Alere, which Abbott bought in late 2017, decreased 4 percent to $537 million from $559 million.

New products included a CE Mark for Abbott’s Determine HBsAg2 rapid diagnostic assay. highly sensitive, easy-to-use, rapid lateral flow test enables identification of those with.  And the company received a CLIA waiver for their BinaxNOW Influenza A & B Card 2 assay.

 

 

A relatively new disease with particular strength in the New York City area but also in 12 U.S. states has seen 617 cases as of time of writing – with particular strength in weakened patients and those in long-term facilities.  Because the fungus is detectable only with complex lab tests such as mass spectrometry, sequencing and novel PCR, test makers once again have an opportunity to demonstrate products can handle novel pathogen threats.

The fungus — Candida auris, also referred to as C. auris —  is treatable with antifungal drugs called echinocandins. However, some C. auris infections are resistant to the main types of medications.   It is particularly found in hospitals and long-term care facilities.   The most common symptoms of invasive Candida infection are fever and chills that don’t improve after antibiotic treatment for a suspected bacterial infection.  While healthy people do not often get the fungus, the CDC is warning all in such facilities to be vigilant about washing hands after patient contact.

The fungal infection tends to target those with compromised immune systems.  Because these are also patients with serious conditions and existing changes of fatality, as many as half may die when contracting the condition, making isolation and treatment early on a key.

[Note – Kalorama covers mycology testing market sizing and forecasting in its report  Infectious Disease Diagnostics, World Market Analysis ]

The disease has taken a particular statistical bent in the New York City area, where two-thirds of the cases were reported.

The fungal infection is tricky to diagnose, though that opens up an opportunity for mass spectrometry-based IVD systems to contribute to detection during the outbreak.

“Diagnostic devices based on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) can differentiate C. auris from other Candida species, but not all the reference databases included in MALDI-TOF devices allow for detection,” according to the CDC guidance.

Sequencing-based molecular methods based on sequencing the D1-D2 region of the 28s rDNA or the Internal Transcribed Region (ITS) of rDNA also can identify C. auris.   Other products, such as PCR, can identify fungal infection absent a specific C. auris designation:

T2 Biosystems’  T2Candida® Panel identify the most serious bacterial and fungal pathogens directly from blood sample in just three to five hours, without waiting for a positive blood culture —which can take one to six or more days.  The FDA-cleared and CE marked test runs on a desktop analyzer based on magnetic resonance imaging and provides results within five hours.

Thermo Fisher’s RapID YEAST PLUS System, a qualitative micromethod employing conventional and chromogenic substrates for the identification of medically important yeast, yeast-like and related organisms which have been isolated from human clinical specimens.  It does not specify C. auris at time of reporting, but can signify candida infection which can suggest further testing.

The CDC also said that laboratories with capability to characterize isolates further when C. auris is suspected are encouraged to do so. Suspected isolates can also be sent to CDC’s AR Lab Network for identification and antifungal susceptibility testing.  This testing is performed free of charge and may require coordination through the State Public Health Department’s Healthcare-associated Infection (HAI) Program.  The CDC advises that Isolates should be submitted on slants shipped at room temperature.   Futher, mycology specific media are not necessary if the laboratory does not have them. C. auris can grow on blood or chocolate agar slants.

In China, reaction to the disease is more stated though cases are also lower and not likely to cause an epidemic in China, according to an article in in China Daily http://www.ecns.cn/news/2019-04-12/detail-ifzhhxra9209972.shtml.  The country’s medical authorities are concentrating on patients with serious disease or undergoing chemotherapy.

 

 

 

 

 

 

 

Pittcon 2019 now in its 70th year, meets in Philadelphia this week.  The meeting is an opportunity to showcase improvements in laboratory technology.  While mass spectrometry and liquid chromatography are key areas for vendors, this year’s meeting will feature a large demonstration space where vendors will show off spectrometry, software and even analyze common everyday beverages to demonstrate their system features.

Bioinformatics Inc., Kalorama Information and related companies will be present with a large team.  Kalorama Information’s partner publication SDi (STRATEGIC DIRECTIONS INTERNATIONAL)  recently published its 80+ instrument market analysis report, Global Assessment 2019, https://bioinfoinc.com/product/2019-sdi-global-report-analytical-life-science-industry/.  The report covers the bulk of the industry at the meeting.

A few noticeable early announcements are on our radar:

 Bruker Biosciences will exhibit a new inert gas fusion (IGF) analyzer.  The new G6 LEONARDOTM is an economic, robust and precise inert gas fusion (IGF) analyzer for oxygen, nitrogen and hydrogen (ONH) concentration measurements in inorganic samples.  With its pre-calibrated standard methods and argon gas instead of helium, the G6 LEONARDO addresses the needs of industrial process and QC for easy and cost-effective operation.

Bruker also announced a new software acquisition intended to help manage pharamceutical projects.  Bruker announced that it has acquired Arxspan LLC , a provider of cloud-based scientific software and workflow solutions. Arxspan is known for its line of cloud-based products for the management of research data, with a focus on serving pharmaceutical and biopharma customers.

“Known-Knowns” and “Unknown-Unknowns”

Among many other show developments and announcements, Thermo Fisher Scientific will host two seminars dedicated to small-molecule.  The company will inform attendees of its new software solutions coupled to a new Orbitrap HRAM mass spectrometer to tackle the challenge of capturing sufficient, high-quality MSn fragmentation spectra for each component within complex samples. The company says these new solutions revolutionize the process and effectiveness of confident compound characterization of known-knowns, known-unknowns, and unknown-unknowns.

In another seminar, Thermo will feature New dual-LC technology and single-quadrupole MS provide opportunities to increase throughput by analyzing samples more efficiently and reduce operational costs by optimizing bench space. Learn how these systems can be used for efficient characterization of (bio)pharmaceuticals, fast method development, and comprehensive separation and detection of complex samples.  The Vanquish Duo for Dual LC houses two flow paths in one system to save space and improve returns.

Waters Corp. will demonstrate it’s Automated PeakTracker in Fusion QbD for Advanced LC and LC/MS Method Development a new platform that dramatically advances chromatographic method development:   Waters Empower CDS with Fusion QbD® Software containing PeakTracker™, the Waters ACQUITY H-Class PLUS UPLC, PDA detection, and ACQUITY QDa Mass Detector.

The company says that PeakTracker is a new automated peak tracking technology that optimizes and simplifies mass detection in the method development workflow. Complex separation challenges addressed includes.  Partially co-eluted peaks assigned the same mass, Completely co-eluted peaks resulting in missing data.

“Beverage Identification” on Display

 Waters is hosting a “Kool Aid Never Looked So Good” Separation Challenge to test sample preparation skills on the exhibit floor Thursday.  Participants will be given two “mystery” samples and some clues about the products. Using solid-phase extraction, they will guess the food dyes, order of elution and complete a separation in less than one minute.   Judging will be based on the accuracy of your guesses and the performance of separation.

PITTCONN Philadelphia will boast two live demo areas where attendees can participate in 20-minute, interactive product demonstrations. The dedicated areas will cover topics such as air monitoring, new techniques in water testing, innovative products to increase lab efficiency, and recent developments in spectroscopy, spectral databases, and techniques for using hazardous materials.  Among the events at the  “Live Demo” areas include:

  • Is your coffee really decaf? Lumex Instruments will test that, using capillary electrophoresis technology.
  • Trajan Scientific and Medical will demonstrate its two automated systems for performing Liquid-Liquid extractions [LLE] on a micro scale. They can be applied as effective alternatives to the time-consuming manual processes
  • Sartorius will exhibit its “Next-Generation” balances for high performance lab use.  Balances feature a 0.1 mg resolution at 64 g, 124 g, or 224 g. capacities.  Each is available with or without an internal calibration weight.
  • Shimadzu Scientific Instruments will display its Elemental Analysis: EDX-7000 X-ray Fluorescence Spectrometer Bench-top energy dispersive X-ray fluorescence instrumentation can provide a safe, fast and easy alternative to more difficult and expensive technologies like Atomic Absorption (AA), Optical Emission Spectroscopy (ICP-OES) and Mass Spectrometry (ICP-MS).
  • Bio-Rad Laboratories will demonstrate its Bio-Rad’s KnowItAll® Solutions, combining  IR & Raman spectroscopy with spectral analysis software
  • HORIBA Scientific will demonstrate in nanoparticle identification, quantification, and sizing by nanoparticle tracking
  • Cerno Bioscience will present its GC/MS Compound ID Using Accurate Mass and Automated Mixture Detection

 

 

 

News came this week that the Department of Veterans Affairs awarded Foundation Medicine, a Cambridge, MA- based molecular testing company, a significant contract to provide genomic profiling for veterans helps to validate the growing use of NGS and liquid biopsy for diagnostics.

The contract was reported to be at 111.5 million over five years. It covers several of Roche-owned Foundation’s tests including Foundation One CDx, Foundation One Liquid, Foundation One Heme. These tests provide profiles that can be used in precision cancer, therapy-matching approaches. The VA said the goal of the program is to provide tumor sequencing for all veterans. 60 hospitals reportedly provide specimens for sequencing, with expansion planned. Prostate cancer is a particular target area, because of the need for early detection and treatment action, according to the agency.
“The development is a validation for the use of these tests, and more broadly, for the approach of performing comprehensive analysis, versus single-gene or small gene panel approaches,” said Justin Saeks, Kalorama Information’s Next Generation Sequencing Survey report that the firm published last year.
Kalorama believes it is good news for Roche, with large potential for service revenues; the company has seen its NGS market share slip consistently despite acquisitions and collaborations.

“The company actually had first-to-market advantage initially in the NGS market, but its share diminished over the years as competitors introduced higher performing, more economical systems and continuously provided upgrades,” Saeks said.
For more information, Kalorama Information’s most recent Next Generation Sequencing Market is located at: https://www.kaloramainformation.com/Generation-Sequencing-Instrumentation-Consumables-Services-Competitive-Trends-11594541/

The size and prestige of the VA could even portend an increased tendency towards services for diagnostics testing, sending tests out to labs, as opposed to the common practice of medical centers running NGS tests in-house. This would be more likely for comprehensive analysis, which requires more sequences to be covered than the tests that analyze small sets of genes

Next-generation sequencing (NGS) in diagnostics is rapidly growing, having made great strides since the conclusion of the Human Genome Project fifteen years ago. Increasingly rapid and effective testing capabilities for hereditary diseases, cancers, cardiac and respiratory conditions, neurodegenerative disorders, and even infectious disease, are either on the horizon or have arrived. The promise of DNA sequencing through this methodology alone has attracted many companies, researchers, and investors.The Worldwide Market forIn VitroDiagnostics, 11th Edition, has been released recently, and features a significant section on molecular diagnostics, including NGS. Below is a selection of developments that have arisen in the period since our report’s August publication.

In July, Genepath Laboratories (Chatswood, NSW, Australia) launched their NextGen test, a genetic screening test for use in detecting multiple treatable conditions, in conjunction with the heel-prick newborn screening test. NextGen can screen for over 60 serious medical conditions—50 of which were not previously tested in Australia—including conditions associated with sudden infant death syndrome (SIDS), life threatening conditions like tyrosinemia and familial hemophagocytic lymphohistiocytosis, conditions that cause developmental disabilities in both physical growth and intellect, conditions leading to heart and lung diseases, and rare cancers. Sample collection for the NGS panel is a simple mouth swab that can be performed on patients of any age, but is best for newborns as the targeted conditions usually appear in the first year of life. Among the conditions tested is familial hypercholesterolemia, a condition—easily treated through diet and medication—that significantly increases risk for myocardial infarction in young adults, and is estimated to be severely underdiagnosed in Australia.

Women’s health company NxGen MDx (Grand Rapids, MI) also announced in July that they had developed a new method of DNA tagging, called active molecular identification (AMI), to track samples and prevent laboratory errors, using synthetic DNA to tag a patient’s sample at the beginning of the testing process. AMI tagging accompanies and identifies the patient’s sample throughout the entire process, and connects it to the final test results, reducing the incidence of sample mixups. Validation studies were conducted to ensure that the synthetic DNA used in the methodology does not affect testing.

Meanwhile, it was announced in August that a five-year NIH grant valued at over $8 million had been awarded for research on the clinical and economic benefits of conducting NGS testing in newborns at multiple institutions, including Cincinnati Children’s Hospital, Mt. Sinai Hospital, Rady Institute for Genomic Medicine, Tufts Medical Center, University of North Carolina-Chapel Hill, and the University of Pittsburgh. Four hundred newborns known to be at high-risk for genetic diseases, but have not yet been diagnosed, will be enrolled in the study and will receive whole-genome and targeted genomic sequencing to test for over 1,700 genetic disorders. The multiplex panel is under development with Quest Diagnostics. Results will be compared with more conventional diagnostic procedures, with focus on time to diagnosis, time to treatment, and the total costs associated with each methodology.

An article to be published in theJournal of Global Antimicrobial Resistance (DOI:10.1016/j.jgar.2018.08.018; available online, currently in press), illustrates the potential of whole-genome sequencing in more rapid and comprehensive diagnosis of drug resistant tuberculosis. A study conducted in Indonesia, which has the world’s second highest TB burden, involved the use of WGS on over 300 samples from HIV-negative TB patients, among which, nearly 16% were found to have drug-resistant strains of the disease. The concurrence rate between WGS-based testing and more conventional phenotypic drug susceptibility testing was high for rifampicin and isoniazid, but less so for streptomycin and ethambutol. A potential advantage of WGS-based testing is that testing by more conventional means has been shown to be poorly corresponded with reported prior treatment for TB, due to clinicians targeting only patients with previous treatment or other risk factors, resulting in many undetected drug-resistant cases. WGS-based testing is potentially helpful in limiting the spread of drug resistant TB by testing patients who lack such risk factors.

In August, Novogene Bioinformatics Technology (Beijing) announced approval for its NovoFocus NSCLC CDx assay by the China Food and Drug Administration. The NGS-based diagnostic analyzes tumor samples for multiple genomic mutations associated with non-small cell lung cancer, which accounts for approximately 80% of all lung cancer cases in China. Results from sequencing and analysis of ROS1, EGFR, and ALK can be used to identify NSCLC patients eligible for treatment with CFDA-approved cancer therapies including Crizotinib (XALKORI), Gefitinib (IRESSA), and Osimertinib (TAGRISSO), respectively. Other genes targeted in the panel are KRAS, BRAF, and PIK3CA. NovoFocus NSCLC CDx was developed on the Thermo Fisher Ion Proton sequencing platform.

Asuragen (Austin, TX) announced in September the expansion of its own oncology portfolio with the launch of their newly CE-markedQuantideX NGS DNA Hotspot 21 Kit. The kit is a next-generation sequencing panel designed to detect numerous tumor types, including those in colorectal cancer, melanoma, and non-small cell lung cancer. QuantideX NGS DNA Hotspot 21 uses Asuragen’s NGS-in-a-Box design and the company’s Sample-Aware bioinformatics software, which determines whether a sample has sufficient DNA that can be amplified. The panel is indicated for use on Illumina’s MiSeq platform.

IDbyDNA (San Francisco) signed a licensing agreement mid-September with Fleury Group (São Paulo, Brazil) to offer the company’sExplify platform for clinical metagenomic testing in South America, with Fleury integrating the platform into its own laboratory operations. Fleury will also develop a full suite of clinical tests for Explify, beginning with a respiratory panel that detects over 200 common, rare, and novel bacterial, viral, and fungal pathogens in respiratory specimens.

IDbyDNA, which developed Explify in collaboration with ARUP Laboratories (Salt Lake City), is in another partnership, begun in January with Locus Biosciences (Morrisville, NC), to develop a diagnostic test for the Explify platform to detect Pseudomonas æruginosa. Locus will use the test to recruit and select patients for its clinical trial for LBx-PA01, a CRISPR-based antimicrobial product that targets the pathogen, which is associated with sepsis and a number of nosocomial infections.

Jerusalem-based NovellusDx will merge with a newly-formed Israeli subsidiary of Cancer Genomics (Rutherford, NJ), which will combine the former’s expansive cancer test portfolio and large tumor biology dataset with the latter’s proprietary NGS and machine learning tech. Cancer Genomics will be the surviving entity, but NovellusDx shareholders will gain a 49% stake in the company as part of the merger agreement.

Miami-based Igenomix has developed the Analysis of Infectious Chronic Endometritis (ALICE), an NGS-based diagnostic for the uterine infection that can lead to infertility in women. As traditional diagnostic methods do not accurately identify the bacteria in endometritis, nonspecific antibiotics are often prescribed and will not always be as effective as the infection requires. ALICE requires just a small endometrial sample from which DNA is extracted; the sample undergoes bacterial analysis through next-generation sequencing. With ALICE, clinicians can detect the correct culprit and prescribe the right pro- and antibiotic to treat the infection, and improve women’s reproductive success.

Again, for the latest market analysis of next-generation sequencing-based IVD, see the eleventh edition of our flagship report,The Worldwide Market forIn VitroDiagnostics, published in August.

Kalorama Information notes 4 trends in monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances – topped $100 billion in 2017, according to Kalorama Information What’s Trending in Monoclonal Antibodies, examines the several types of monoclonal antibodies on the market and in development, looking at the mAbs market by structure, by target, and by indication.

  • Humanized mAbs Grow: Advancements in human and humanized monoclonal antibodies will be the major areas of development and growth through 2022.  Humanized mAbs will outpace all other structure types with compound annual growth of 13.5%.  More than $20 billion in revenues will be generated from new approvals in humanized mAbs over the forecast.
  • Watch for growth from PD-1 and PD-L1 mAbs.  These segments will show some of the strongest increases over the forecast.  Cancer indications are driving sales in these categories and are expected to maintain pace, increasing at CAGR of 38.4% for PD-1 and 21.5% for PD-L1 from 2017-2022.  Interleukin mAbs will also enjoy strong adoption.  More than $25 billion will come from developments and approvals between 2018 and 2022.
  • Neuro mAbs a Particular Focus: Steady growth is expected from oncology and autoimmune disease categories, as expected.  But new growth is projected in the neurological  segment with many mAb development programs moving froward in the area of Alzheimer’s disease.
  • United States First: The U.S. is the strongest mAb market with 56% market share and expected to maintain growth, accounting for 57% of the market in 2022, or $97 billion, an increase of 11.6%.

Further, the report discusses the several factors contributing to the strong growth of the monoclonal antibodies market. Company profiles of the major participants in the mAbs market are provided as well. What’s Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication) can be found at: https://www.kaloramainformation.com/Trending-Monoclonal-Antibodies-Structure-Target-Indication-11440829/.

 

 New York City-based healthcare market researcher Kalorama Information details the top 10 liquid biopsy companies and their activities in a new report.  The market, Kalorama says, is heterogeneous and very fragmented, with many companies commercializing various liquid biopsy diagnostic products and developing new ones for a broad range of applications.  But a few top competitors can be expected to stay in long-term.  Roche, Qiagen, Biocept and Myriad Genetics are among the companies on the list.  The report indicates that in 2017, more than 40 companies are active in the global market for liquid biopsy diagnostic and monitoring tests.  These are detailed in the report, The Worldwide Market for Liquid Biopsy, the first major study to look at the market and define competitor performance and market sizing from an independent, healthcare specialist market research firm.


ROCKVILLE, Med in recent years as a result of new product introductions, and is projected to continue to increase within the next five years, as many companies are developing new products that are expected to reach the market in the near future.  The market growth will be influenced by factors such as the rising incidence and prevalence of cancer at the global level, increasing use of personalized medicine, regulatory hurdles, reimbursement considerations, and adoption and integration issues of these.

Kalorama Information’s Report The Worldwide Market for Liquid Biopsy (by Analyte [ctDNA, cfDNA, Other], by Application – Screening/Drug Monitoring/Diagnostic, by Region [US, EuropeAsia, ROW] and by Type of Cancer) is available at: https://www.kaloramainformation.com/prod-toc/Worldwide-Liquid-Biopsy-Analyte-ctDNA-cfDNA-Application-Screening-Drug-Monitoring-Diagnostic-Region-Europe-Asia-ROW-Type-Cancer-10975987/.